Francisco J. Altimiras

  • Citations Per Year
Learn More
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability. Previous studies have implicated mGlu5 in the pathogenesis of the disease, and many agents that target the underlying pathophysiology of FXS have focused on mGluR5 modulation. In the present work, a novel pharmacological approach for FXS is investigated. NNZ-2566, a(More)
Alzheimer's disease (AD) is the most common cause of dementia, affecting more than 36 million people worldwide. Octodon degus, a South American rodent, has been found to spontaneously develop neuropathological signs of AD, including amyloid-β (Aβ) and tau deposits, as well as a decline in cognition with age. Firstly, the present work introduces a novel(More)
Retraction: "Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566" by R. M. J. Deacon, M. J. Hurley, C. M. Rebolledo, M. Snape, F. J. Altimiras, L. Farías, M. Pino, R. Biekofsky, L. Glass and P. Cogram. The above article, from Genes, Brain and Behavior, published online on 12th May 2017 in Wiley Online Library(More)
1 Faculty of Engineering and Sciences, Universidad Adolfo Ibañez, Santiago, Chile, 2 Telefonica Research and Development, Santiago, Chile, 3 Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain, 4 Universitat Pompeu Fabra, Barcelona, Spain, 5 Institute of Psychiatry, Psychology and Neuroscience, King’s College(More)
  • 1